secwatch / observer
8-K filed June 5, 2023, 7:59 PM ET CIK 0001169987
other material confidence high sentiment negative materiality 1.00

HTG MOLECULAR DIAGNOSTICS, INC: going-concern / distress — HTG Molecular Diagnostics files Chapter 11; debt of $2.7M accelerated; CCO terminated

HTG MOLECULAR DIAGNOSTICS, INC

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Byron T. Lawson

Senior Vice President and Chief Commercial Officer
HTG MOLECULAR DIAGNOSTICS, INC
Effective
2023-06-02
Filed
June 5, 2023, 7:59 PM ET
On June 1, 2023, the Company notified Byron T. Lawson, Senior Vice President and Chief Commercial Officer of the Company, of his termination of employment, effective June 2, 2023.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

HTG MOLECULAR DIAGNOSTICS, INC faced acceleration on credit facility of $2,687,255 with Silicon Valley Bank, N.A., a division of First-Citizens Bank and Trust Company.

Instrument
credit facility
Principal
$2,687,255
Counterparty
Silicon Valley Bank, N.A., a division of First-Citizens Bank and Trust Company
Event
acceleration
Exact text from the filing
The filing of the Case constituted an event of default that accelerated all of the Company’s obligations under the Company’s Loan and Security Agreement, dated June 24, 2020, as amended, with Silicon Valley Bank, N.A., a division of First-Citizens Bank and Trust Company (“Loan Agreement”), comprising an outstanding principal amount of $2,687,255, together with accrued interest and all applicable fees and other financial obligations.
View on SEC.gov
Distress & Bankruptcy SEC 8-K Item 1.03 confidence 0.9

HTG MOLECULAR DIAGNOSTICS, INC entered chapter 11 in United States Bankruptcy Court for the District of Delaware (petition 2023-06-05).

Proceeding
chapter 11
Court
United States Bankruptcy Court for the District of Delaware
Petition
2023-06-05
Exact text from the filing
On June 5, 2023 (the “Petition Date”), HTG Molecular Diagnostics, Inc. (the “Company”) filed a voluntary petition (Case No. 23-10732) for relief under Chapter 11 of the United States Bankruptcy Code (the “Code”) in the United States Bankruptcy Court for the District of Delaware
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Byron T. Lawson was terminated as Senior Vice President and Chief Commercial Officer at HTG MOLECULAR DIAGNOSTICS, INC.

Action
terminated
Role
Senior Vice President and Chief Commercial Officer
Exact text from the filing
On June 1, 2023, the Company notified Byron T. Lawson, Senior Vice President and Chief Commercial Officer of the Company, of his termination of employment, effective June 2, 2023.
View on SEC.gov

41 debt financings filed in the last 30 days. Browse all debt financings →

Source: SEC EDGAR
accession 0000950170-23-026337
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.